Floatz logo

TACROLIMUS

Progressive Supranuclear Palsy

Peking University First HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Progressive Supranuclear Palsy cohort.

Asset / SponsorPhaseRating
IOFLUPANE
GE Healthcare
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
Riluzole
King's College London
Phase 3B
[18F]MNI-958
Invicro
Phase 1B
Droxidopa
Loma Linda University
Phase 2CCC

View all 12 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →